Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.

ABSTRACT:

Background

Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illness.

Methods

In the prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising antibody titres (50% neutralisation titre (NT₅₀)) ≥1/320 was the product of choice for the study.

Results

Between 2 May 2020 and 26 January 2021, 320 patients were random

SUBMITTER: Devos T 

PROVIDER: S-EPMC8576805 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature